Company / Operating Income
ORAMED PHARMACEUTICALS INC. Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$12.8M
FY2025
5-year range
-$40.6M / -$11.8M
FY2021-FY2025
Trend
+18.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has fluctuated over the past 10 years, ranging from -$41M in FY2023 to -$6M in FY2016.
Based on SEC 10-K filings.
-$13M in FY2025.
Improved from -$41M to -$13M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income increased 18.9% year-over-year.
- Peak operating income was recorded in FY2016.
- Lowest operating income in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$12.8M | +18.9% |
| FY2024 | -$15.8M | +61.2% |
| FY2023 | -$40.6M | -67.6% |
| FY2022 | -$24.2M | -106.0% |
| FY2021 | -$11.8M | +19.6% |
| FY2020 | -$14.6M | -35.8% |
| FY2019 | -$10.8M | -7.6% |
| FY2018 | -$10.0M | -35.6% |
| FY2017 | -$7.4M | -25.0% |
| FY2016 | -$5.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026